Illumina, Inc. announced on February 21, 2025, a collaboration with Broad Clinical Labs to rapidly streamline and scale single-cell projects. This partnership aims to set a new standard for scalable single-cell research and accelerate the development of a 5 billion cell atlas within the next three years.
The collaboration combines Illumina's Single Cell Prep, NovaSeq™ X Plus platform, 25B flow cell, and DRAGEN™ analysis software with Broad Clinical Labs' deep experience in translating complex molecular biology assays into high-throughput workflows. This end-to-end solution will enable the processing and analysis of unprecedented volumes of single-cell reads with high speed and accuracy.
Broad Clinical Labs will utilize this workflow alongside state-of-the-art techniques such as Perturb-seq and CRISPR screens. These capabilities are expected to make large-scale functional genomics studies possible, accelerating discovery in critical areas like disease modeling and drug development.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.